ERT has completed the acquisition of Boston-based PHT Corporation (PHT), the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research. Financial terms of the transaction were not disclosed.

The acquisition will help ERT position itself as the leader in eClinical Outcome Assessments (eCOA) and patient-centric data collection. ERT offers clinical trial and healthcare technologies, along with consulting services. The combined company will have an increased global footprint throughout North America, Europe and Asia, supporting all phases of clinical research across a broad range of therapeutic areas for small and mid-sized biopharma to CROs and large pharmaceutical companies, including the top 30 pharmaceutical companies in the world.

“By combining our organizations, we have strengthened our capabilities to deliver the most innovative and comprehensive patient-centric data collection solutions during this era of accelerated eCOA adoption,” said Jim Corrigan, President and CEO of ERT. “We are excited to leverage our respective strengths as we continue our focus on accelerating clinical research to help bring new therapies to market.”

Over the coming weeks, ERT will provide additional details on how this acquisition will further enhance the company’s ability to bring novel patient-centric solutions to the clinical research industry.